Background: Type 2 Diabetes Mellitus (T2DM) is a multifactorial disease that is influenced by genetic, metabolic, and environmental factors. Genetic predisposition, obesity, low physical activity, and unhealthy diet are key risk factors for T2DM. Result: Type 2 diabetes is treated with various natural medicines, the most significant of which is berberine (BBR). Berberine, an isoquinoline alkaloid found in various medicinal plants, exhibits a wide range of pharmacological activities and (BBR) has the potential to treat various diseases, such as diabetes, cancer, and metabolic and cardiovascular diseases. Conclusion: It has been found to be effective in AMPK activation, regulation of blood glucose and lipids, stimulation of insulin secretion from pancreatic beta cells, inhibition of cancer cells, and reduction of fat formation.
References
[1]
Global Health Organization. https://www.who.int/ar/news-room/fact-sheets/detail/diabetes
[2]
Purwaningsih, I., Maksum, I.P., Sumiarsa, D. and Sriwidodo, S. (2023) A Review of Fibraurea tinctoria and Its Component, Berberine, as an Antidiabetic and Antioxidant. Molecules, 28, Article 1294. https://doi.org/10.3390/molecules28031294
[3]
Chang, W., Chen, L. and Hatch, G.M. (2015) Berberine as a Therapy for Type 2 Diabetes and Its Complications: From Mechanism of Action to Clinical Studies. Biochemistry and Cell Biology, 93, 479-486. https://doi.org/10.1139/bcb-2014-0107
[4]
Leslie, R.D., Palmer, J., Schloot, N.C. and Lernmark, A. (2015) Diabetes at the Crossroads: Relevance of Disease Classification to Pathophysiology and Treatment. Diabetologia, 59, 13-20. https://doi.org/10.1007/s00125-015-3789-z
[5]
Paschou, S.A., Papadopoulou-Marketou, N., Chrousos, G.P. and Kanaka-Gantenbein, C. (2018) On Type 1 Diabetes Mellitus Pathogenesis. Endocrine Connections, 7, R38-R46. https://doi.org/10.1530/ec-17-0347
[6]
Schmidt, A.M. (2018) Highlighting Diabetes Mellitus: The Epidemic Continues. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, e1-e8. https://doi.org/10.1161/atvbaha.117.310221
[7]
Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., et al. (2021) The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Oxidative Medicine and Cellular Longevity, 2021, Article ID: 2074610. https://doi.org/10.1155/2021/2074610
[8]
Shrivastava, S., Sharma, A., Saxena, N., Bhamra, R. and Kumar, S. (2023) Addressing the Preventive and Therapeutic Perspective of Berberine against Diabetes. Heliyon, 9, e21233. https://doi.org/10.1016/j.heliyon.2023.e21233
[9]
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., et al. (2020) Pathophysiology of Type 2 Diabetes Mellitus. International Journal of Molecular Sciences, 21, Article 6275. https://doi.org/10.3390/ijms21176275
[10]
Ibrahim, N.A.B. (2023) An Introduction to Diabetes. Frontiers in Health Informatics, 12, Article 129. https://doi.org/10.30699/fhi.v12i0.405
[11]
Panigrahi, A. and Mohanty, S. (2023) Efficacy and Safety of HIMABERB® Berberine on Glycemic Control in Patients with Prediabetes: Double-Blind, Placebo-Controlled, and Randomized Pilot Trial. BMC Endocrine Disorders, 23, Article No. 190. https://doi.org/10.1186/s12902-023-01442-y
[12]
Grant, R.W. and Dixit, V.D. (2013) Mechanisms of Disease: Inflammasome Activation and the Development of Type 2 Diabetes. Frontiers in Immunology, 4, Article 50. https://doi.org/10.3389/fimmu.2013.00050
[13]
Guamán Ortiz, L., Lombardi, P., Tillhon, M. and Scovassi, A. (2014) Berberine, an Epiphany against Cancer. Molecules, 19, 12349-12367. https://doi.org/10.3390/molecules190812349
[14]
Singh, A., Duggal, S., Kaur, N. and Singh, J. (2010) Berberine: Alkaloid with Wide Spectrum of Pharmacological Activities. https://www.scienceopen.com/document?vid=cd6accdf-33ed-4057-b738-ba21e744cef1
[15]
Wang, L., Liu, D., Wei, G. and Ge, H. (2021) Berberine and Metformin in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Clinical Trials. Health, 13, 1314-1329. https://doi.org/10.4236/health.2021.1311096
[16]
Ali, F., Alom, S. and Zaman, M.K. (2021) Berberine: A Comprehensive Review on Its Isolation, Biosynthesis, Chemistry and Pharmacology. Asian Journal of Chemistry, 33, 2548-2560. https://doi.org/10.14233/ajchem.2021.23365
[17]
Gao, Y., Wang, F., Song, Y. and Liu, H. (2020) The Status of and Trends in the Pharmacology of Berberine: A Bibliometric Review [1985-2018]. Chinese Medicine, 15, Article No. 7. https://doi.org/10.1186/s13020-020-0288-z
[18]
Ndidi Iheme, K., Ayiwue, Pierre, Hailemeskel, B., Smith, S.A. and Kulkarni, A. (2023) Review of Berberine Use for the Treatment of Type 2 Diabetes Mellitus & Students’ Survey. International Journal of Science and Research Archive, 9, 034-040. https://doi.org/10.30574/ijsra.2023.9.1.0342
[19]
Yin, J., Ye, J. and Jia, W. (2012) Effects and Mechanisms of Berberine in Diabetes Treatment. Acta Pharmaceutica Sinica B, 2, 327-334. https://doi.org/10.1016/j.apsb.2012.06.003
[20]
Utami, A.R., Maksum, I.P. and Deawati, Y. (2023) Berberine and Its Study as an Antidiabetic Compound. Biology, 12, Article 973. https://doi.org/10.3390/biology12070973
[21]
Yang, X., Yang, C. and Lu, W. (2023) Berberine Suppresses Gestational Diabetes in Streptozotocin-Induced Diabetes Mellitus Rats by Suppression of Inflammatory Mediators. Indian Journal of Pharmaceutical Education and Research, 57, 423-431. https://doi.org/10.5530/ijper.57.2.53
[22]
Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., et al. (2019) Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics. Theranostics, 9, 1923-1951. https://doi.org/10.7150/thno.30787
[23]
Yin, J., Xing, H. and Ye, J. (2008) Efficacy of Berberine in Patients with Type 2 Diabetes. Metabolism, 57, 712-717. https://doi.org/10.1016/j.metabol.2008.01.013
[24]
Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., et al. (2022) Glucose-lowering Effect of Berberine on Type 2 Diabetes: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 13, Article 1015045. https://doi.org/10.3389/fphar.2022.1015045
